专利快速检索-快速检索全球专利，免费商用专利数据库-IPRDB

1. 发明申请

US20060159669A1 Novel uses of PPAR modulators and professional APCs manipulated by the same 审中-公开
标题翻译： PPAR调制器和专业APCs的新用途被操纵
公开(公告)号：US20060159669A1
公开(公告)日：2006-07-20
申请号：US11273003
申请日：2005-11-14
申请人： Laszlo Nagy , Istvan Szatmari , Eva Rajnavolgyi , Peter Gogolak , Bence Rethi
发明人： Laszlo Nagy , Istvan Szatmari , Eva Rajnavolgyi , Peter Gogolak , Bence Rethi
IPC分类号： A61K48/00 , A61K39/00 , C12N5/08
CPC分类号： C12N5/0639 , A61K47/6901 , A61K2035/122 , A61K2035/124 , C12N5/064 , C12N2501/385
摘要： The invention relates to a manipulated professional antigen presenting cell (APC) having increased expression of a CD1 type II molecule, preferably at least a CD1d molecule, relative to a control non manipulated cell. The invention further relates to the use of PPARg modulators in the preparation of a pharmaceutical composition or kit for the treatment of a disease treatable by activation of CD1d restricted T-cells, e.g. in autoimmune diseases, allergies, post-transplant conditions or infectious diseases, or in the treatment of a neoplastic disease, e.g. skin cancer, hematological tumors, colorectal carcinoma, and therapeutic compositions and kits therefor. Furthermore, the invention relates to methods of manipulating professional APCs and kits therefor.
摘要翻译：本发明涉及相对于对照非操纵细胞具有增加的CD1型II分子表达，优选至少一种CD1d分子的操纵的专业抗原呈递细胞（APC）。本发明还涉及PPARg调节剂在制备药物组合物或试剂盒中的用途，所述药物组合物或试剂盒用于治疗通过激活CD1d限制性T细胞可治疗的疾病，例如，自身免疫性疾病，过敏症，移植后状况或感染性疾病，或治疗肿瘤性疾病，例如，皮肤癌，血液肿瘤，结肠直肠癌，及其治疗组合物和试剂盒。此外，本发明涉及操纵专业APC及其工具包的方法。

2. 发明授权

US09371290B2 Pyridazinone compounds 有权
标题翻译：哒嗪酮化合物
公开(公告)号：US09371290B2
公开(公告)日：2016-06-21
申请号：US14003626
申请日：2012-03-06
申请人： Marjo Pihlavisto , David Smith , Auni Juhakoski , Ferenc Fulop , Laszlo Lazar , Istvan Szatmari , Ferenc Miklos , Zsolt Szakonyi , Lorand Kiss , Marta Palko
发明人： Marjo Pihlavisto , David Smith , Auni Juhakoski , Ferenc Fulop , Laszlo Lazar , Istvan Szatmari , Ferenc Miklos , Zsolt Szakonyi , Lorand Kiss , Marta Palko
IPC分类号： A61K31/50 , A61K31/501 , C07D401/00 , C07D403/00 , C07D405/00 , C07D409/00 , C07D237/24 , C07D405/14 , C07D401/04 , C07D403/04 , C07D405/04 , C07D409/04 , C07D413/04 , C07D401/14 , A61K31/5377 , A61K45/06 , C07D237/16 , C07D403/12 , C07D403/14 , G01N33/50
CPC分类号： C07D237/24 , A61K31/4439 , A61K31/496 , A61K31/50 , A61K31/501 , A61K31/5377 , A61K45/06 , C07C57/15 , C07D237/16 , C07D401/04 , C07D401/14 , C07D403/04 , C07D403/12 , C07D403/14 , C07D405/04 , C07D405/14 , C07D409/04 , C07D413/04 , G01N33/502
摘要： The invention relates to pyridazinone and pyridone compounds having formula (I) or (I′), and pharmaceutically acceptable salts, hydrates, and solvates thereof (I) wherein R1/R4 and X and X3 are as defined in the claims. The invention further relates to their use as inhibitors of copper-containing amine oxidases. The present invention also relates to the preparation of the aforementioned compounds and to pharmaceutical compositions comprising as an active ingredient(s) one or more of the aforementioned compounds, pharmaceutically acceptable salts, hydrates, or solvates thereof.
摘要翻译：本发明涉及具有式（I）或（I'）的哒嗪酮和吡啶酮化合物及其药学上可接受的盐，水合物和溶剂合物（I），其中R1 / R4和X和X3如权利要求中所定义。本发明还涉及它们作为含铜胺氧化酶抑制剂的用途。本发明还涉及上述化合物的制备以及包含一种或多种上述化合物，药学上可接受的盐，水合物或溶剂合物作为活性成分的药物组合物。

3. 发明授权

US5888536A Liposome composition containing selegilin 失效
标题翻译：含有selegilin的脂质体组成
公开(公告)号：US5888536A
公开(公告)日：1999-03-30
申请号：US817433
申请日：1997-08-05
申请人： Michael Mezei , Jozsef Gaal , Gabor Szekacs , Gyula Szebeni , Katalin Marmarosi , Kalman Magyar , Jozsef Lengyel , Istvan Szatmari , Agnes Turi
发明人： Michael Mezei , Jozsef Gaal , Gabor Szekacs , Gyula Szebeni , Katalin Marmarosi , Kalman Magyar , Jozsef Lengyel , Istvan Szatmari , Agnes Turi
IPC分类号： A61K9/127 , A61K31/135 , A61K31/137 , A61K47/42 , A61P25/00 , A61P25/28 , A61K31/13
CPC分类号： A61K31/137 , A61K9/127
摘要： This invention provides liposomic composition, containing as active ingredient (-)-N-.alpha.-dimethyl-N-(2-propynylphenylethylamine) (selegilin) and/or salt thereof. This composition contains: 0.1-40% by weight of selegilin and/or a salt thereof, 2 to 40% by weight of lipids, preferably phospholipids, 0 to 10% by weight of cholesterol, 0 to 20% by weight of an alcohol, 0 to 25% by weight of a glycol, 0 to 3% by weight of an antioxidant, 0 to 3% by weight of a preserving agent, 0 to 2% by weight of a viscosity influencing agent, 0 to 50% by weight of cyclodextrin or a cyclodextrin derivative and 30 to 90% by weight of water. This invention relates to pharmaceutical composition, containing the liposomic composition described and if desired, usual filling and diluting agents and other auxiliaries, preferably in oral, parenteral or transdermal form. This invention provides the process for the preparation of liposomic compositions containing selegilin and/or salt thereof. Accordingly liposomic composition of this invention may be administered for the treatment of Alzheimeir's disease, Parkinson's disease, depression, stroke, motion sickness or myelitis.
摘要翻译： PCT No.PCT / HU95 / 00052 Sec。 371日期：1997年8月5日 102（e）日期1997年8月5日PCT 1995年10月20日PCT PCT。第WO96 / 12472号公报日期：1996年5月2日本发明提供含有作为（ - ） - N-α-二甲基-N-（2-丙炔基苯乙胺）（selegilin）和/或其盐的活性成分的脂质体组合物。该组合物含有：0.1-40重量％的赛莱格林和/或其盐，2〜40重量％的脂质，优选磷脂，0〜10重量％的胆固醇，0〜20重量％的醇， 0〜25重量％的二醇，0〜3重量％的抗氧化剂，0〜3重量％的防腐剂，0〜2重量％的粘度影响剂，0〜50重量％环糊精或环糊精衍生物和30〜90重量％的水。本发明涉及包含所述脂质体组合物和如果需要的通常的填充和稀释剂和其它助剂的药物组合物，优选口服，肠胃外或透皮形式。本发明提供了制备含有塞来昔林和/或其盐的脂质体组合物的方法。因此，本发明的脂质体组合物可以用于治疗阿尔茨海默病，帕金森病，抑郁症，中风，运动病或脊髓炎。

4. 发明申请

US20140024648A1 NEW PYRIDAZINONE AND PYRIDONE COMPOUNDS 有权
标题翻译：新的吡咯烷酮和吡咯烷酮化合物
公开(公告)号：US20140024648A1
公开(公告)日：2014-01-23
申请号：US14003626
申请日：2012-03-06
申请人： Marjo Pihlavisto , David Smith , Auni Juhakoski , Ferenc Fulop , Laszlo Lazar , Istvan Szatmari , Ferenc Miklos , Zsolt Szakonyi , Lorand Kiss , Marta Palko
发明人： Marjo Pihlavisto , David Smith , Auni Juhakoski , Ferenc Fulop , Laszlo Lazar , Istvan Szatmari , Ferenc Miklos , Zsolt Szakonyi , Lorand Kiss , Marta Palko
IPC分类号： C07D237/24 , A61K31/501 , A61K45/06 , A61K31/50 , C07D403/12 , C07D401/04 , C07D405/04 , C07D413/04 , C07D409/04 , C07D403/14 , A61K31/5377 , C07D401/14 , C07D237/16 , C07D405/14 , G01N33/50 , C07D403/04
CPC分类号： C07D237/24 , A61K31/4439 , A61K31/496 , A61K31/50 , A61K31/501 , A61K31/5377 , A61K45/06 , C07C57/15 , C07D237/16 , C07D401/04 , C07D401/14 , C07D403/04 , C07D403/12 , C07D403/14 , C07D405/04 , C07D405/14 , C07D409/04 , C07D413/04 , G01N33/502
摘要： The invention relates to pyridazinone and pyridone compounds having formula (I) or (I′), and pharmaceutically acceptable salts, hydrates, and solvates thereof (I) wherein R1/R4 and X and X3 are as defined in the claims. The invention further relates to their use as inhibitors of copper-containing amine oxidases. The present invention also relates to the preparation of the aforementioned compounds and to pharmaceutical compositions comprising as an active ingredient(s) one or more of the aforementioned compounds, pharmaceutically acceptable salts, hydrates, or solvates thereof.
摘要翻译：本发明涉及具有式（I）或（I'）的哒嗪酮和吡啶酮化合物及其药学上可接受的盐，水合物和溶剂合物（I），其中R1 / R4和X和X3如权利要求中所定义。本发明还涉及它们作为含铜胺氧化酶抑制剂的用途。本发明还涉及上述化合物的制备以及包含一种或多种上述化合物，药学上可接受的盐，水合物或溶剂合物作为活性成分的药物组合物。

5. 发明授权

US3982736A Intensification of fluid-fluid transport processes 失效
标题翻译：液体输送过程的强化
公开(公告)号：US3982736A
公开(公告)日：1976-09-28
申请号：US471821
申请日：1974-05-20
申请人： Lajos Meszaros , Jozsef Grega , Lajos Lako , Laszlo Marko , Zoltan Salamon , Istvan Szatmari , Laszlo Tasi
发明人： Lajos Meszaros , Jozsef Grega , Lajos Lako , Laszlo Marko , Zoltan Salamon , Istvan Szatmari , Laszlo Tasi
IPC分类号： B01F7/00 , B01F7/16 , B01F13/00 , B01F15/00 , B01F7/20
CPC分类号： B01F7/00558 , B01F13/00 , B01F7/16
摘要： Transport processes such as emulsification, mass transfer, dissolution, washing or chemical reaction are carried out by admixing two substantially immiscible fluid phases with a rotary agitator having thereon filamentary elements that occupy 0.1% to 20% of the space to be swept thereby, whose thickness is 10-5000 .mu.m and whose thickness-to-length ratio is 1:5 to 1:5000, there being several thousand such elements on the rotor, that rotates at several thousand rpm, the elements having peripheral speed of at least 30 m/s.-- The operation is improved by also including in the fluid medium solid particles of a size 1-1000 .mu.m.
摘要翻译：运输过程如乳化，传质，溶解，洗涤或化学反应是通过将两个基本上不混溶的流体相与旋转搅拌器混合来进行的，所述旋转搅拌器具有占据待扫掠空间的0.1％至20％的丝状元素，其厚度为10-5000μm，其厚度比为1:5至1:5000，转子上有数千个元件，以几千rpm转动，圆周速度至少为30m / .-通过在流体介质中还包括尺寸为1-1000μm的固体颗粒来改善操作。

6. 发明授权

US5589513A Pharmaceutical composition and process for the preparation thereof 失效
标题翻译：药物组合物及其制备方法
公开(公告)号：US5589513A
公开(公告)日：1996-12-31
申请号：US256128
申请日：1994-06-17
申请人： Kalman Magyar , Jozsef Gaal , Istvan Sziraki , Jozsef Lengyel , Anna Z. Szabo , Katalin Marmarosi , Istvan Hermecz , Istvan Szatmari , Zoltan Torok , Peter Kormoczy
发明人： Kalman Magyar , Jozsef Gaal , Istvan Sziraki , Jozsef Lengyel , Anna Z. Szabo , Katalin Marmarosi , Istvan Hermecz , Istvan Szatmari , Zoltan Torok , Peter Kormoczy
IPC分类号： A61K45/00 , A61K20060101 , A61K31/135 , A61K31/137 , A61K45/06 , A61P25/24 , A61P25/26 , A61P25/28 , C07C43/00 , C07C205/00 , C07C217/00 , A01N33/02
CPC分类号： A61K31/135
摘要： The invention relates to two phase pharmaceutical compositions comprising as active ingredient a MAO inhibitor and an uptake inhibitor together with usual pharmaceutical auxiliaries. The compositions can be used for the treatment of neurodegenerative diseases. As active ingredient optionally N-(1-phenyl-isopropyl)-N-methyl-propinylamine or N-(4-fluoro-phenyl)-isoprop-1-yl-N-methyl-propinylamine or their salts, optically active isomers or metabolites are used both as MAO inhibitor and as uptake inhibitor.
摘要翻译： PCT No.PCT / HU92 / 00060 Sec。 371日期：1994年6月17日 102（e）日期1994年6月17日PCT提交1992年12月18日PCT公布。公开号WO93 / 12775 PCT 日期：1993年7月8日本发明涉及包含作为活性成分的MAO抑制剂和吸收抑制剂以及通常的药物助剂的两相药物组合物。该组合物可用于治疗神经变性疾病。作为活性成分，任选地N-（1-苯基 - 异丙基）-N-甲基 - 丙烯胺或N-（4-氟 - 苯基） - 异丙基-1-基-N-甲基 - 丙基胺或其盐，旋光异构体或代谢物被用作MAO抑制剂和摄取抑制剂。

你已经成功收藏专利！

检索式保存成功!

IPRDB

热门服务

关于我们

友情链接

联系方式